Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 227

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 227
---
,656 |
| ​                                                                                     | ​ |                                 |       ​ | ​ |   |         |
| Supplemental disclosure of cash flow information:                                     | ​ |                                 |       ​ | ​ |   |         |
| Cash paid for interest                                                                | ​ | $                               |   1,352 | ​ | $ |   2,710 |
| ​                                                                                     | ​ |                                 |         | ​ |   |         |
| Supplemental disclosure of noncash activities:                                        | ​ |                                 |         | ​ |   |         |
| Issuance of common shares - Founders Agreement                                        | ​ | $                               |   1,109 | ​ | $ |   4,212 |
| Note payable final payment fee (incurred but not paid)                                | ​ | $                               |       — | ​ | $ |   1,050 |
| Issuance of warrants - note payable                                                   | ​ | $                               |       — | ​ | $ |     384 |
| Lease liabilities arising from obtaining right-of-use assets                          | ​ | $                               |       — | ​ | $ |   2,176 |

**See accompanying notes to financial statements.

F-7

Notes to Financial Statements

Note 1 - Organization and Description of Business Mustang Bio, Inc. (the “Company” or “Mustang”) was incorporated in Delaware on March 13, 2015. Mustang is as a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is a majority-controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”). The Company’s common stock is listed on the Nasdaq Capital Market and trades under the symbol “MBIO.” Reverse Stock Split On March 3, 2023, the Board of Directors of the Company (the “Board”) unanimously adopted resolutions to approve and recommend stockholder approval of a form amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding Common Stock within a range of between 5-for-1 and 20-for-1 (with our Board being authorized to determine the exact ratio),